Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With more than 40 novel agents already pending at FDA, 2013 looks like a good bet to repeat the strong NME and novel biologic approval counts of 2012 and 2011. Big pharma and big markets dominate the 2013 slate so far, especially with diabetes, respiratory and central nervous system candidates.

Advertisement

Related Content

Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology
Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
GSK Is Getting Ready For A Return To The ’90s
FDA Wants To Help You Develop Drugs
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
Rejuvenated Roche’s Pipeline Promises Innovation, Profitability
Genentech Resubmits T-DM1 To FDA, This Time With An Overall Survival Benefit
Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights
For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel